Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 earnings results
Harmony Biosciences Holdings, Inc. (HRMY) reported Q3 2026 results on Nov 4, 2026, 8:00:11 AM ET: GAAP EPS $0.81 vs. $1.47 expected (miss by 44.8%); revenue $268.92M vs. $272.05M expected (miss by 1.2%). Outlook: Reiterates full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $0.81 | $1.47 | Miss by 44.8% |
| Revenue | $268.92M | $272.05M | Miss by 1.2% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 4, 2026, 8:00:11 AM ET. Nexqual published them 48 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 12.3% from $239.46M; GAAP diluted EPS was $0.81 vs. $0.87 (−6.9%).
Stock reaction
The results came out before the market opened. HRMY closed at $34.42 on November 4, 2026, down 7.0% from its $37.02 close on November 3, 2026 before the results. Latest: $33.45 as of 11:53 AM ET, −9.6% since the pre-release close.
Questions and answers
Did Harmony Biosciences Holdings, Inc. beat earnings expectations?
No. Harmony Biosciences Holdings, Inc. reported GAAP EPS of $0.81 against an average analyst estimate of $1.47 (miss by 44.8%), and revenue of $268.92M against $272.05M expected (miss by 1.2%).
What were Harmony Biosciences Holdings, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $0.81 and revenue of $268.92M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 12.3% from $239.46M; GAAP diluted EPS was $0.81 vs. $0.87 (−6.9%).
When did Harmony Biosciences Holdings, Inc. report Q3 2026 earnings?
Nov 4, 2026, 8:00:11 AM ET, in an SEC 8-K filing (Item 2.02).
How did HRMY stock react to the earnings?
The results came out before the market opened. HRMY closed at $34.42 on November 4, 2026, down 7.0% from its $37.02 close on November 3, 2026 before the results. Latest: $33.45 as of 11:53 AM ET, −9.6% since the pre-release close.
What did Harmony Biosciences Holdings, Inc. say about its outlook?
Reiterates full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
More on HRMY
HRMY stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 4, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:53 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt